“We are proud to celebrate our 20th anniversary,” said Dr. Olga Potapova, CEO of Cureline. “We have
accomplished a lot over the past two decades, but we are just getting started”.
Since our founding in 2003, we have been committed to advancing the science and technology of
human health and disease, with a focus on oncology, immunology, infectious diseases, and rare
Our mission is to deliver innovative solutions that address unmet needs and improve biomedical
research worldwide. We achieve this by leveraging our expertise in biomarker discovery and validation,
biobanking, and biospecimen management. We also collaborate with leading academic institutions,
pharmaceutical and biotechnology companies, and non-profit organizations to accelerate the discovery
and development of new therapies and diagnostics.
Over the past two decades, we have achieved several accomplishments, including: Over the past two
decades, we have achieved several accomplishments, including:
- Establishing a global network of biobanks that adhere to the highest quality, ethics, and
- Successfully completed over 5,000+ projects with more than 700+ clients worldwide, including
leading pharmaceutical and biotechnology companies, academic institutions, and government
- Contributed to discovering and validating new biomarkers and therapeutic targets for various
diseases such as cancer, autoimmune disorders, infectious diseases, neurological disorders,
metabolic disorders, and rare diseases.
- Participation in several international consortia and initiatives such as the Cancer Genome Atlas
(TCGA) and The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
- Cureline Group has been recognized as a global leader in HBS biobanking and translational CRO
services by several industry awards and publications such as Biobanking.com3, Bloomberg
Markets, Pharma Tech Outlook, CIO Review, etc.
At Cureline, we are committed to accelerating the implementation of scientific breakthroughs for the
betterment of patients worldwide. Our team works closely with our clients to develop customized HBS
procurement protocols that effectively meet their research objectives and comply with all regulatory
“We are honored to celebrate this milestone with our clients, clinical partners, and employees who have
supported us throughout the years,” said Olga Potapova, Ph.D., founder, and CEO of Cureline. “We are
grateful for the trust and confidence they have placed in us, and we look forward to continuing to
provide them with the best HBS and translational CRO solutions for their research goals.”
Thank you for being part of our story.
To learn more about Cureline and its global biobanking and translational CRO services, please visit
www.cureline.com or contact firstname.lastname@example.org.